Chemoprevention of colorectal cancer - A new target needed?

Colorectal Disease

Volumn 9, Issue 5, 2007, Pages 397-401

  Spychalski, Michal ^a   Dziki, L ^a   Dziki, A ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Chemoprevention; Colorectal cancer; Cyclo oxygenase 2; NF B

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; K RAS PROTEIN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; ROFECOXIB; SULINDAC; VALDECOXIB;

ADENOMATOUS POLYP; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER PREVENTION; CANCER RISK; CARCINOGENESIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COLON CANCER; COLORECTAL ADENOMA; COLORECTAL CANCER; DRUG CONTRAINDICATION; DRUG SAFETY; DRUG SELECTIVITY; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; GENE EXPRESSION REGULATION; HUMAN; LONG TERM CARE; METASTASIS; NONHUMAN; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; RISK REDUCTION;

ADENOMATOUS POLYPOSIS COLI; COLORECTAL NEOPLASMS; CYCLOOXYGENASE 2 INHIBITORS; FEMALE; HUMANS; MALE; NF-KAPPA B P50 SUBUNIT; RANDOMIZED CONTROLLED TRIALS;

EID: 34248641697     PISSN: 14628910     EISSN: 14631318     Source Type: Journal    
DOI: 10.1111/j.1463-1318.2006.01166.x     Document Type: Article

References (39)

1. Landis S, Murray T, Bolden S et al. Cancer statistics. CA Cancer J Clin 1998; 48: 6-29.
2. Ries LAG, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg L, Mariotto A, Feuer EJ, Edwards BK. (eds). (2005) SEER Cancer Statistics Review, 1975-2002. National Cancer Institute, Bethesda, MD. http://seer.cancer.gov/csr/1975_2002/, based on November 2004 SEER data submission, posted to the SEER web site 2005.
3. Montoya RG, Wargovich MJ. Chemoprevention of gastrointestinal cancer. Cancer Metastasis Rev 1997; 16: 405-19.
4. Tomeo CA, Colditz GA, Willett WC, Giovannucci E, Platz E, Rockhill B, Dart H, Hunter DJ. Harvard report on cancer prevention. Cancer causes and control 1999; 10: 167-80.
5. Hong WK, Lippman SM, Itri LM, Karp DD, Lee JS, Byers RM, Schantz SP, Kramer AM, Lotan R, Peters LJ. Prevention of second primary tumors with isotretinoin un squamous cell carcinoma of the head and neck. N Engl J Med 1990; 323: 795-801.
6. Smith R, von Eschenbach A, Wender R et al. American Cancer Society Guidlines for early detection of cancer:UPdate of early detection guidlines for prostate, colorectal and endometrial cancers. CA Cancer J Clin 2001; 51: 38-75.
7. Burt R. Colon cancer screening. Gastroenterology 2000; 119: 837-53.
8. Buecher B, Thouminot C, Menanteau J, Bonnet C, Jarry A, Heymann MF, Cherbut C, Galmiche JP, Blottiere HM. Fructooligosaccharide associated with celecoxib reduces the number of aberrant crypt foci in the colon of rats. Reprod Nutr Dev 2003; 43: 347-56.
9. Wei M, Morimura K, Wanibuchi H, Shen J, Doi K, Mitsuhashi M, Moku M, Salim EI, Fukushima S. Chemopreventive effect of JTE-522, a selective cyclooxygenase-2 inhibitor, on 1, 2-dimethylhydrazine-induced rat colon carcinogenesis. Cancer Lett 2003; 202: 11-6.
10. Brown WA, Skinner SA, Malcontenti-Wilson C, Misajon A, DeJong T, Vogiagis D, O'Brien PE. Non-steroidal anti-inflammatory drugs with different cyclooxygenase inhibitory profiles that prevent aberrant crypt foci formation but vary in acute gastrotoxicity in a rat model. J Gastroenterol Hepatol 2000; 15: 1386-92.
11. Mahmoud NN, Dannenberg AJ, Mestre J, Bilinski RT, Churchill MR, Martucci C, Newmark H, Bertagnolli MM. Aspirin prevents tumors in a murine model of familial adenomatous polyposis. Surgery 1998; 124: 225-31.
12. Giardiello FM, Hamilton SR, Krush AJ, Piantadosi S, Hylind LM, Celano P et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. New Engl J Med 1993; 328: 1313-6.
13. Jacoby RF, Seibert K, Cole CE, Kelloff G, Lubet RA. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. Cancer Res 2000; 60: 5040-4.
14. Wu GS et al. Celecoxib inhibits proliferation and induces apoptosis via prostaglandin E2 pathway in human cholangiocarcinoma cell lines. World J Gastroenterol 2003; 9: 1302-6.
15. Thun MJ, Hennekenn CH. (2001 6th edition) Aspirin and other non-steroidal anti-inflammatory drugs and the risk of cancer development. In: Cancer: Principles and Practice of Oncology (eds DeVitt VT, Hellman S, Rosenberg SA), pp. 601-7. Lippincott Williams & Wilkins Press, Philadelphia.
16. Shiff SJ, Rigas B. Non steroidal anti-inflamatory drugs and colorectar cancer: Evolving concepts of their chemopreventive actions. Gastroenterology 1997; 113: 1992-8.
17. Williams CS, Smalley W, DuBois RN. Aspirin use and potential mechanisms for colorectal cancer prevention. J Clin Invest 1997; 100: 1325-9.
18. Lazzaroni M, Bianchi Porro G. Gastrointestinal side-effects of traditional non-steroidal anti-inflammatory drugs and new formulations. Aliment Pharmacol Ther 2004; 20 (Suppl. 2): 48-58.
19. Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000; 342: 1946-52.
20. Bresalier RS, Sandler RS, Quan H et al. Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005; 352: 1092-102.
21. Juni P, Nartey L, Reichenback S, Sterchi R, Dieppe P, Matthias E. Risk of cardiovascular events and rofecoxib: Cumulative meta-analysis. Lancet 2004; 364: 2021-9.
22. Hallak A, Alon-Baron L, Shamir R, Moshkowitz M, Bulvik B, Brazowski E, Halpern Z, Arber N. Rofecoxib reduces polyp recurrence in familial polyposis. Dig Dis Sci 2003; 48: 1998-2002.
23. Eberhart CE, Coffey RJ, Radihika A, Giardiello FM, Ferrenbach S, DuBois RN. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994; 107: 1183-8.
24. Wu AW, Gu J, Ji JF, Li ZF, Xu GW. Role of COX-2 in carcinogenesis of colorectal cancer and its relationship with tumer biological characteristics and patients prognosis. World J Gastroenterol 2003; 9: 1990-4.
25. Kitamura T, Itoh M, Noda T, Matsubara M, Wakabayashi K. Combined effects of cyclooxygenase-1 and cyclooxygenase-2 selective inhibitors on intestinal tumorgenesis in Adenomatous Polyposis Coli gene knockout mice. Int J Cancer 2004; 109: 576-80.
26. Oshima M, Dinchuk JE, Kargman SL, Oshima H, Hancock B, Kwong E, Trzaskos JM, Evans JF, Taketo MM. Suppression of intestinal polyposis in Apce delta716 knockout mice by inhibition of cyclooxygenase 2. Cell 1996; 87: 803-9
27. Williams CS, Mann M, DuBois RN. The role of cyclooxygenases in inflamation, cancer and developement. Oncogene 1999; 18: 7908-16.
28. Casibang M, Purdom S, Jakolew S et al. Prostaglandin E2 and vasoactive intestinal peptide increase vascular endothelial cell growth factor mRNAs in lung cancer cells. Lung Cancer 2001; 31: 203-12.
29. Bing RJ, Miyataka M, Rich KA et al. Nitric oxide, prostanoids, cyclooxygenase and angiogenesis in colon and breast cancer. Clin Cancer Res 2001; 7: 3385-92.
30. Grosch S, Tegeder I, Niederberger E, Brautingam L, Geisslinger G. Cox-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by selective COX-2 inhibitor, celecoxib. FASEB J 2001; 15: 2742-4.
31. Kawamori T, Uchiya N, Sugimura T, Wakabayashi K. Enhancement of colon carcinogenesis by prostaglandin E2 administration. Carcinogenesis 2003; 24: 985-90.
32. Bottone FG Jr, Martinez JM, Alston-Mills B, Eling TE. Gene modulation by Cox-1 and Cox-2 specific inhibitors in human colorectal carcinoma cancer cells. Carcinogenesis 2004; 25: 349-57. Epub 2003 Nov 21.
33. Hsu AL, Ching TT, Wang DS, Song X, Rangnekar VM, Chen CS. The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells indepedently of Bcl-2. J biol Chem 2000; 275: 11397-403.
34. Bos JL, Fearon ER, Hamilton SR, Verlaan-de Vries M, van Boom JH, van der Eb AJ, Vogelstein B. Prevalence of ras gene mutations in human colorectal cancers. Nature 1987; 327: 293-7.
35. Takada Y, Khuri F, Aggawal BB. Protein farnesyltransferase inhibitor (SCH 66336) abolishes NF-kappaB activation induced by various carcinogens and inflammatory stimuli leading to suppression of NF-kappaB-regulated gene expression and up-regulation of apoptosis. J Biol Chem 2004; 279: 26287-99.
36. Anrather J, Csizmadia V, Soares MP, Winkler H. Regulation of NF-kappaB RelA phosphorylation and transcriptional activity by p21(ras) and protein kinase Czeta in primary endothelial cells. J Biol Chem 1999; 274: 13594-603.
37. Shishodia S, Koul D, Aggarwal BB. Cyclooxygenase (COX)-2 inhibitor celecoxib abrogates TNF-induced NF-kappa B activation through inhibition of activation of I kappa B alpha kinase and Akt in human non-small cell lung carcinoma: Correlation with suppression of COX-2 synthesis. J Immunol 2004; 173: 2011-22.
38. Roche-Nagle G, Connolly EM, Eng M, Bouchier-Hayes DJ, Harmey JH. Antimetastatic activity of a cyclooxygenase-2 inhibitor. Br J Cancer 2004; 91: 359-65.
39. Wu C-Y, Wang C-J, Tseng C-C et al. Helicobacter pylori promote gastric cancer cells invasion through a NF-κB and COX-2-mediated pathway. World J Gastroenterol 2005; 11: 3197-203.